UPL Limited

“UPL is a leveraged generic agrochemical platform that permanently impaired its return profile through the 2019 Arysta acquisition, halving ROCE to ~7.7% while doubling debt. At INR 608, the stock trades 30-45% above intrinsic value on normalized earnings, pricing in a near-complete cyclical recovery while offering no margin of safety for a business that earns below its cost of capital. Free cash flow is consumed by debt service, the moat is narrowing under Chinese generic competition, and a second downcycle before deleveraging completes poses existential risk to equity holders. Capital is far better deployed in asset-light, high-return Indian agrochemical peers.”